Prototype code that could change your life? Adverse Events The most important AE is death. Only two in the vaccine arm, four in the placebo. The Ns were 21,621 vaccine and 21,631 placebo, two doses for both, three weeks apart. Deaths were heart attacks, strokes, and two unknowns in the placebo group. All older than 55. This data is, of course, in favor of the vaccine. Others (S is “serious”): “The most common SAEs in the vaccine group which were numerically higher than in the placebo group were appendicitis (0.04%), acute myocardial infarction (0.02%), and cerebrovascular accident (0.02%), and in the placebo arm numerically higher than in the vaccine arm were pneumonia (0.03%), atrial fibrillation (0.02%), and syncope [passing out] (0.02%).” The placebo AEs can be put down to anxiety, if you like, or usual disease with the pneumonia. Appendicitis is indeed serious, as are heart attacks (MIs); and “cerebrovascular accident” is a nice euphemism for stroke. Next, tables of “solicited” and “unsolicited” AEs. The difference is those the experimenters thought to ask about and those they didn’t. This opens the possibility that unsolicited AEs are under-counted. Click the image to enlarge. With our assumption about cause, the vaccine has been confirmed to produce more AEs. Click the image to enlarge. Note that this table (above) is 18-55 only, but a chart for 55+ is similar. Pain, swelling, and redness, while greater with vaccines, are minor. I won’t show it, but there are similar charts showing vaccines produce in 18-55 year olds more fever (15.8% vs. 0.5%) fatigue (59.4% vs. 22.8%), headaches (51.7% vs. 24.1%), chills (35.1% vs. 3.8%), vomiting (1.9% vs. 1.2%), diarrhea (10.4% vs. 8.4%), muscle pain (37.3% vs. 8.2%), joint pain (21.9% vs. 5.2%), and use of antipyretic or anti-pain meds (45 vs. 12.6%). Results are similar for 55+. Whether these are important is a question for you, and not anybody else. Meaning the answer will vary depending on person. -William Briggs Regards, George Gilder Editor, Gilder's Daily Prophecy |
No comments:
Post a Comment